N-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2α and telomerase activity

Acta Pharmacologica Sinica

Volumn 30, Issue 9, 2009, Pages 1297-1306

  Wei, Chyou Wei ^a   Lin, Chai Ching ^b   Yu, Yung Luen ^c,d   Lin, Chai Yi ^b   Lin, Po Cheng ^e   Wu, Min Tze ^f   Chen, Cheng Jueng ^g   Chang, Wenliang ^h   Lin, Shinn Zong ^c   Chen, Yi Lin Sophia ^b   Harn, Horng Jyh ^c  

^a HUNGKUANG UNIVERSITY   (Taiwan)

^b NATIONAL ILAN UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^f TAIWAN AGRICULTURAL RESEARCH INSTITUTE   (Taiwan)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^h NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

AP 2 xenograft; Human telomerase reverse transcriptase; Immunohistochemistry; N butylidenephthalide

Indexed keywords

ANTINEOPLASTIC AGENT; MYC PROTEIN; N BUTYLIDENEPHTHALIDE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; PHTHALIC ANHYDRIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TELOMERASE; TRANSCRIPTION FACTOR AP-2; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70249099877     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.124     Document Type: Article

References (40)

1. Blackburn EH. Telomerases. Annu Rev Biochem 1992; 61: 113-129
2. Greider CW, Blackburn EH. A telomeric sequence in the RNA of tetrahymena telomerase required for telomere repeat synthesis. Nature 1989; 337: 331-337
3. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-573
4. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995; 269: 1236-1241
5. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959
6. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997; 17: 498-502.
7. Boldrini L, Faviana P, Gisfredi S, Zucconi Y, Di Quirico D, Donati V, et al. Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med 2002; 10: 589-592
8. Janknecht R. On the road to immortality: Htert upregulation in cancer cells. FEBS Lett 2004; 564: 9-13.
9. Kanaya T, Kyo S, Takakura M, Ito H, Namiki M, Inoue M. Htert is a critical determinant of telomerase activity in renal-cell carcinoma. Int J Cancer 1998; 78: 539-543
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015
11. Nakano K, Watney E, McDougall JK. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am J Pathol 1998; 153: 857-864
12. Park TW, Riethdorf S, Riethdorf L, Loning T, Janicke F. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int J Cancer 1999; 84: 426-431
13. Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst 1995; 87: 884-894
14. Katakura Y, Yamamoto K, Miyake O, Yasuda T, Uehara N, Nakata E, et al. Bidirectional regulation of telomerase activity in a subline derived from human lung adenocarcinoma. Biochem Biophys Res Commun 1997; 237: 313-317
15. Lee JC, Jong HS, Yoo CG, Han SK, Shim YS, Kim YW. Telomerase activity in lung cancer cell lines and tissues. Lung Cancer 1998; 21: 99-103.
16. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999; 20: 1649-1651
17. Taga S, Osaki T, Ohgami A, Imoto H, Yasumoto K. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg 1999; 230: 715-720
18. Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89: 1609-1615
19. Bilsland AE, Stevenson K, Atkinson S, Kolch W, Keith WN. Transcriptional repression of telomerase RNA gene expression by c-jun-NH2kinase and sp1/sp3. Cancer Res 2006; 66: 1363-1370
20. Kirkpatrick KL, Ogunkolade W, Elkak AE, Bustin S, Jenkins P, Ghilchick M, et al. Htert expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-myc expression. Breast Cancer Res Treat 2003; 77: 277-284
21. Ma H, Urquidi V, Wong J, Kleeman J, Goodison S. Telomerase reverse transcriptase promoter regulation during myogenic differentiation of human RD rhabdomyosarcoma cells. Mol Cancer Res 2003; 1: 739-746
22. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004; 40: 1485-1495
23. Li H, Goswami PC, Domann FE. Ap-2gamma induces p21 expression, arrests cell cycle, and inhibits the tumor growth of human carcinoma cells. Neoplasia 2006; 8: 568-577
24. Baldi A, Santini D, Battista T, Dragonetti E, Ferranti G, Petitti T, et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001; 83: 364-372
25. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. Apoptosis induction by activator protein 2alpha involves transcriptional repression of bcl-2. J Biol Chem 2006; 281: 16207-16219
26. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 2004; 64: 631-638
27. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, et al. Loss of AP-2 results in up-regulation of mcam/muc18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998; 273: 16501-16508
28. Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietilainen T, Bohm J, et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res 2002; 8: 3487-3495
29. Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, et al. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer 2000; 82: 1974-1983
30. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, et al. Hypermethylation of a small cpguanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 2004; 64: 1611-1620
31. Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, Bar- Eli M. Dominant-negative transcription factor AP-2 augments sb-2 melanoma tumor growth in vivo. Oncogene 2001; 20: 3363-3375
32. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, et al. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005; 11: 267-272
33. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, et al. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 2001; 54: 533-538
34. Kao ST, Yeh CC, Hsieh CC, Yang MD, Lee MR, Liu HS, et al. The Chinese medicine bu-zhong-yi-qi-tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci 2001; 69: 1485-1496
35. Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, Chang WL, et al. The antitumor effects of angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 2005; 11: 3475-3484
36. Tsai NM, Chen YL, Lee CC, Lin PC, Cheng YL, Chang WL, et al. The natural compound n-butylidenephthalide derived from angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem 2006; 99: 1251-1262
37. Lin PC, Chen YL, Chiu SC, Yu YL, Chen SP, Chien MH, et al. Orphan nuclear receptor, nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem 2008; 106: 1017-1026
38. Chen YL, Jian MH, Lin CC, Kang JC, Chen SP, Lin PC, et al. The induction of orphan nuclear receptor nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy. Mol Pharmacol 2008; 74: 1046-1058
39. Budiyanto A, Bito T, Kunisada M, Ashida M, Ichihashi M, Ueda M. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma. J Invest Dermatol 2003; 121: 1088-1094
40. Kunisada M, Budiyanto A, Bito T, Nishigori C, Ueda M. Retinoic acid suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma. Br J Dnermatol 2005; 152: 435-443